NASDAQ:ADXS - Advaxis Stock Price, News & Analysis

$0.40
-0.01 (-2.41 %)
(As of 08/18/2019 04:00 PM ET)
Today's Range
$0.3550
Now: $0.4050
$0.4130
50-Day Range
$0.40
MA: $1.10
$2.28
52-Week Range
$0.35
Now: $0.4050
$23.70
Volume922,000 shs
Average Volume1.03 million shs
Market Capitalization$6.97 million
P/E RatioN/A
Dividend YieldN/A
Beta3.23
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADXS
CUSIPN/A
Phone609-452-9813

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.06 million
Book Value$5.18 per share

Profitability

Net Income$-66,510,000.00
Net Margins-126.12%

Miscellaneous

Employees58
Market Cap$6.97 million
Next Earnings Date9/9/2019 (Estimated)
OptionableOptionable

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.


Advaxis (NASDAQ:ADXS) Frequently Asked Questions

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) announced its quarterly earnings results on Monday, June, 10th. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.19) by $0.13. The biotechnology company earned $1.19 million during the quarter, compared to analyst estimates of $0.34 million. Advaxis had a negative net margin of 126.12% and a negative return on equity of 86.88%. View Advaxis' Earnings History.

When is Advaxis' next earnings date?

Advaxis is scheduled to release their next quarterly earnings announcement on Monday, September 9th 2019. View Earnings Estimates for Advaxis.

What price target have analysts set for ADXS?

1 brokerages have issued 1 year price objectives for Advaxis' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Advaxis' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 887.7% from the stock's current price. View Analyst Price Targets for Advaxis.

What is the consensus analysts' recommendation for Advaxis?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis.

What are Wall Street analysts saying about Advaxis stock?

Here are some recent quotes from research analysts about Advaxis stock:
  • 1. According to Zacks Investment Research, "Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P. " (8/9/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Neutral rating of ADXS and our 12-month price target of $4.30 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple (6x 2026 sales estimate at 20% discount); and (2) price-earnings multiple (19x 2026 earnings estimate at 20% discount)." (6/12/2019)

Has Advaxis been receiving favorable news coverage?

Headlines about ADXS stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Advaxis earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Advaxis.

Who are some of Advaxis' key competitors?

What other stocks do shareholders of Advaxis own?

Who are Advaxis' key executives?

Advaxis' management team includes the folowing people:
  • Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
  • Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
  • Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
  • Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
  • Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)

Who are Advaxis' major shareholders?

Advaxis' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.91%), Vanguard Group Inc. (1.34%) and JPMorgan Chase & Co. (0.30%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit, Roni Appel and Sara Bonstein. View Institutional Ownership Trends for Advaxis.

Which institutional investors are buying Advaxis stock?

ADXS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc. and JPMorgan Chase & Co.. View Insider Buying and Selling for Advaxis.

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $0.4050.

How big of a company is Advaxis?

Advaxis has a market capitalization of $6.97 million and generates $6.06 million in revenue each year. The biotechnology company earns $-66,510,000.00 in net income (profit) each year or ($19.34) on an earnings per share basis. Advaxis employs 58 workers across the globe.View Additional Information About Advaxis.

What is Advaxis' official website?

The official website for Advaxis is http://www.advaxis.com/.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]


MarketBeat Community Rating for Advaxis (NASDAQ ADXS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  332 (Vote Outperform)
Underperform Votes:  342 (Vote Underperform)
Total Votes:  674
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel